-
Something wrong with this record ?
Interferon-regulated suprabasin is essential for stress-induced stem-like cell conversion and therapy resistance of human malignancies
S. Hubackova, M. Pribyl, L. Kyjacova, A. Moudra, R. Dzijak, B. Salovska, H. Strnad, V. Tambor, T. Imrichova, J. Svec, P. Vodicka, R. Vaclavikova, L. Rob, J. Bartek, Z. Hodny,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2017
Free Medical Journals
from 2007 to 1 year ago
PubMed Central
from 2007
Europe PubMed Central
from 2007
ProQuest Central
from 2007-06-01
Health & Medicine (ProQuest)
from 2007-06-01
Wiley Free Content
from 2007
Wiley-Blackwell Open Access Titles
from 2007
ROAD: Directory of Open Access Scholarly Resources
from 2007
- MeSH
- Anoikis drug effects radiation effects MeSH
- Azacitidine pharmacology MeSH
- Drug Resistance, Neoplasm MeSH
- Antigens, Differentiation genetics MeSH
- Interferons pharmacology MeSH
- Humans MeSH
- Mice, Inbred BALB C MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Neoplastic Stem Cells drug effects metabolism radiation effects MeSH
- Neoplasm Proteins genetics MeSH
- Neoplasms drug therapy genetics radiotherapy MeSH
- Antineoplastic Agents pharmacology MeSH
- Gene Expression Regulation, Neoplastic drug effects radiation effects MeSH
- Up-Regulation drug effects radiation effects MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Radiation and chemotherapy represent standard-of-care cancer treatments. However, most patients eventually experience tumour recurrence, treatment failure and metastatic dissemination with fatal consequences. To elucidate the molecular mechanisms of resistance to radio- and chemotherapy, we exposed human cancer cell lines (HeLa, MCF-7 and DU145) to clinically relevant doses of 5-azacytidine or ionizing radiation and compared the transcript profiles of all surviving cell subpopulations, including low-adherent stem-like cells. Stress-mobilized low-adherent cell fractions differed from other survivors in terms of deregulation of hundreds of genes, including those involved in interferon response. Exposure of cancer cells to interferon-gamma but not interferon-beta resulted in the development of a heterogeneous, low-adherent fraction comprising not only apoptotic/necrotic cells but also live cells exhibiting active Notch signalling and expressing stem-cell markers. Chemical inhibition of mitogen-activated protein kinase/ERK kinase (MEK) or siRNA-mediated knockdown of extracellular signal-regulated kinase 1/2 (Erk1/2) and interferon responsible factor 1 (IRF1) prevented mobilization of the surviving low-adherent population, indicating that interferon-gamma-mediated loss of adhesion and anoikis resistance required an active Erk pathway interlinked with interferon signalling by transcription factor IRF1. Notably, a skin-specific protein suprabasin (SBSN), a recently identified oncoprotein, was among the top scoring genes upregulated in surviving low-adherent cancer cells induced by 5-azacytidine or irradiation. SBSN expression required the activity of the MEK/Erk pathway, and siRNA-mediated knockdown of SBSN suppressed the low-adherent fraction in irradiated, interferon-gamma- and 5-azacytidine-treated cells, respectively, implicating SBSN in genotoxic stress-induced phenotypic plasticity and stress resistance. Importantly, SBSN expression was observed in human clinical specimens of colon and ovarian carcinomas, as well as in circulating tumour cells and metastases of the 4T1 mouse model. The association of SBSN expression with progressive stages of cancer development indicates its role in cancer evolution and therapy resistance.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023862
- 003
- CZ-PrNML
- 005
- 20250506113124.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/1878-0261.12480 $2 doi
- 035 __
- $a (PubMed)30919591
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Hubackova, Sona $u Laboratory of Genome Integrity, Institute of Molecular Genetics of the ASCR, v. v. i., Prague, Czech Republic. Molecular Therapy Group, Institute of Biotechnology, Czech Academy of Sciences, BIOCEV, Vestec, Prague-West, Czech Republic.
- 245 10
- $a Interferon-regulated suprabasin is essential for stress-induced stem-like cell conversion and therapy resistance of human malignancies / $c S. Hubackova, M. Pribyl, L. Kyjacova, A. Moudra, R. Dzijak, B. Salovska, H. Strnad, V. Tambor, T. Imrichova, J. Svec, P. Vodicka, R. Vaclavikova, L. Rob, J. Bartek, Z. Hodny,
- 520 9_
- $a Radiation and chemotherapy represent standard-of-care cancer treatments. However, most patients eventually experience tumour recurrence, treatment failure and metastatic dissemination with fatal consequences. To elucidate the molecular mechanisms of resistance to radio- and chemotherapy, we exposed human cancer cell lines (HeLa, MCF-7 and DU145) to clinically relevant doses of 5-azacytidine or ionizing radiation and compared the transcript profiles of all surviving cell subpopulations, including low-adherent stem-like cells. Stress-mobilized low-adherent cell fractions differed from other survivors in terms of deregulation of hundreds of genes, including those involved in interferon response. Exposure of cancer cells to interferon-gamma but not interferon-beta resulted in the development of a heterogeneous, low-adherent fraction comprising not only apoptotic/necrotic cells but also live cells exhibiting active Notch signalling and expressing stem-cell markers. Chemical inhibition of mitogen-activated protein kinase/ERK kinase (MEK) or siRNA-mediated knockdown of extracellular signal-regulated kinase 1/2 (Erk1/2) and interferon responsible factor 1 (IRF1) prevented mobilization of the surviving low-adherent population, indicating that interferon-gamma-mediated loss of adhesion and anoikis resistance required an active Erk pathway interlinked with interferon signalling by transcription factor IRF1. Notably, a skin-specific protein suprabasin (SBSN), a recently identified oncoprotein, was among the top scoring genes upregulated in surviving low-adherent cancer cells induced by 5-azacytidine or irradiation. SBSN expression required the activity of the MEK/Erk pathway, and siRNA-mediated knockdown of SBSN suppressed the low-adherent fraction in irradiated, interferon-gamma- and 5-azacytidine-treated cells, respectively, implicating SBSN in genotoxic stress-induced phenotypic plasticity and stress resistance. Importantly, SBSN expression was observed in human clinical specimens of colon and ovarian carcinomas, as well as in circulating tumour cells and metastases of the 4T1 mouse model. The association of SBSN expression with progressive stages of cancer development indicates its role in cancer evolution and therapy resistance.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a anoikis $x účinky léků $x účinky záření $7 D023102
- 650 _2
- $a diferenciační antigeny $x genetika $7 D000943
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a azacytidin $x farmakologie $7 D001374
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a regulace genové exprese u nádorů $x účinky léků $x účinky záření $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a interferony $x farmakologie $7 D007372
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední BALB C $7 D008807
- 650 _2
- $a nádorové proteiny $x genetika $7 D009363
- 650 _2
- $a nádory $x farmakoterapie $x genetika $x radioterapie $7 D009369
- 650 _2
- $a nádorové kmenové buňky $x účinky léků $x metabolismus $x účinky záření $7 D014411
- 650 _2
- $a upregulace $x účinky léků $x účinky záření $7 D015854
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pribyl, Miroslav $u Laboratory of Genome Integrity, Institute of Molecular Genetics of the ASCR, v. v. i., Prague, Czech Republic.
- 700 1_
- $a Kyjacova, Lenka $u Laboratory of Genome Integrity, Institute of Molecular Genetics of the ASCR, v. v. i., Prague, Czech Republic.
- 700 1_
- $a Moudra, Alena $u Laboratory of Genome Integrity, Institute of Molecular Genetics of the ASCR, v. v. i., Prague, Czech Republic.
- 700 1_
- $a Dzijak, Rastislav $u Laboratory of Genome Integrity, Institute of Molecular Genetics of the ASCR, v. v. i., Prague, Czech Republic.
- 700 1_
- $a Salovska, Barbora $u Laboratory of Genome Integrity, Institute of Molecular Genetics of the ASCR, v. v. i., Prague, Czech Republic.
- 700 1_
- $a Strnad, Hynek $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics of the ASCR, v. v. i., Prague, Czech Republic.
- 700 1_
- $a Tambor, Vojtech $u Biomedical Research Center, University Hospital Hradec Kralove, Czech Republic.
- 700 1_
- $a Imrichova, Terezie $u Laboratory of Genome Integrity, Institute of Molecular Genetics of the ASCR, v. v. i., Prague, Czech Republic.
- 700 1_
- $a Svec, Jiri $u Laboratory of Cell and Developmental Biology, Institute of Molecular Genetics of the ASCR, v. v. i., Prague, Czech Republic. Department of Radiotherapy and Oncology, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Vodicka, Pavel $u Department of the Molecular Biology of Cancer, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic. Institute of Biology and Medical Genetics, 1st Medical Faculty, Charles University, Prague, Czech Republic.
- 700 1_
- $a Vaclavikova, Radka $u Laboratory of Pharmacogenomics, Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Rob, Lukas $u Department of Gynecology and Obstetrics, Third Faculty of Medicine, Vinohrady University Hospital, Charles University, Prague, Czech Republic.
- 700 1_
- $a Bártek, Jiří, $d 1953- $u Laboratory of Genome Integrity, Institute of Molecular Genetics of the ASCR, v. v. i., Prague, Czech Republic. Danish Cancer Society Research Center, Copenhagen, Denmark. Department of Medical Biochemistry and Biophysics, Division of Genome Biology, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden. $7 xx0046271
- 700 1_
- $a Hodny, Zdenek $u Laboratory of Genome Integrity, Institute of Molecular Genetics of the ASCR, v. v. i., Prague, Czech Republic.
- 773 0_
- $w MED00167281 $t Molecular oncology $x 1878-0261 $g Roč. 13, č. 7 (2019), s. 1467-1489
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30919591 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20250506113123 $b ABA008
- 999 __
- $a ok $b bmc $g 1596181 $s 1114538
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 13 $c 7 $d 1467-1489 $e 20190610 $i 1878-0261 $m Molecular oncology $n Mol Oncol $x MED00167281
- LZP __
- $a Pubmed-20201125
